Allos Therapeutics' (ALTH) FOLOTYN First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
